Expect continued downward pressure from the overhang of potential conversion shares, as the lender can convert at a deep discount to market. Monitor for the registration statement filing (due by July 1, 2026) which will enable resale of conversion shares, likely accelerating selling. The small cash infusion ($663k new) is insufficient to fund operations for long, raising the risk of further dilutive financings.
Price Chart
Executive Summary
CERO Therapeutics entered into an amended and restated convertible promissory note with SRX Health Solutions, providing up to $1,413,600 in net proceeds (with 25% OID) of which $663,600 was newly funded. The note carries a 10% interest rate, matures May 2027, and is convertible into common stock at a deeply discounted variable price (floor $0.05 or 80% of the 5 lowest intraday prices over 20 days). The terms are highly dilutive and signal financial distress, as the company is raising minimal cash on predatory terms from a single lender.
Key Financial Metrics
Key Facts
- Maximum loan amount of $1,413,600 net proceeds ($1,767,000 principal with 25% OID); $750,000 previously funded, $663,600 new funding on June 23, 2026.
- Conversion price is the lesser of $0.05 (floor) or 80% of the average of the 5 lowest intraday trading prices over the prior 20 days.
- 10% annual interest, maturity May 28, 2027.
- Company must file a resale registration statement for conversion shares by July 1, 2026.
- Lender is limited to 4.99% beneficial ownership cap.
Financial Impact
Up to $1,413,600 in gross proceeds, but with 25% OID the effective cash received is $1,413,600 against a $1,767,000 principal. Conversion at deep discount will cause substantial dilution; exact share count depends on stock price at conversion.
Risk Factors
- Massive dilution from conversion of the note at deeply discounted prices.
- Limited cash runway; additional dilutive financing likely needed.
- Potential default if stock price remains low and conversion terms become even more unfavorable to existing shareholders.
- Registration of conversion shares could lead to immediate selling pressure.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-072602 |
| Document: ea0296022-8k_cero.htm | 0001213900-26-072602 |
| Document: 0001213900-26-072602-index-headers.html | 0001213900-26-072602 |
| Document: 0001213900-26-072602-index.html | 0001213900-26-072602 |
| Document: 0001213900-26-072602.txt | 0001213900-26-072602 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | 8-K | $0.0120 $0.0105 | ▲ +12.50% | ▲ +13.68% | $0.0110 (+8.33%) |
Jul 13, 2026 11w ago | 25-NSE | $0.0150 $0.0100 | ▲ +33.33% | ▲ +36.52% | $0.0110 (+26.67%) |
Jun 26, 2026 14w ago | 8-K | $0.0110 $0.009700 | ▲ +11.82% | ▲ +11.56% | $0.0110 (+0.00%) |
Mar 11, 2026 29w ago | 8-K | $0.0350 $0.0340 | ▲ +2.86% | ▲ +3.38% | $0.0110 (+68.57%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access